PAVING THE WAY FOR AN ALS CURE
By digging deeper into the cause of ALS, and studying the varying sub-forms of the disease, we are developing precision medications that can effectively cure ALS. The three sub-forms of ALS we are currently developing precision medicine for are:
OUR PATIENTS
ALS has a devastating impact on patients and families. Through DNA analysis and clinical studies we now know that there are a number of sub-forms of ALS that should be treated with a precision medicine to have success. Through our work with stem cells from ALS patients and our close collaborators in the clinic and the world-wide ALS research community we have identified three sub-forms of ALS for which we have identified the disease cause. A large group of ALS patients have a hyperactive motor system which leads to rapid disease progression. We are developing a medicine to bring this activity back to normal levels. There is a sub-form of ALS patients that have a malfunctioning cellular waste clearance system. QurAlis is developing a medicine to boost this system to clear toxic proteins from the motor neurons in these patients. The largest group of genetically identifiable ALS patients who have C9orf72 mutations generate large amounts of toxic proteins. QurAlis is developing a device that clears these toxic proteins from the brain and spinal fluids.
For ALS patients in the Tri-state area, please visit the website of the MAC Angels for more information and support: https://www.macangels.org/
OUR MISSION
The mission of QurAlis is to cure ALS using precision medicine. ALS is a destructive disease which causes muscle paralysis through degeneration of the motor system. An ALS diagnosis is a death sentence to patients, with a predicted life expectancy of about 3 years following diagnosis. ALS can affect anyone.
MESSAGES OF HOPE
We can defeat ALS. We have brought world class ALS researchers, doctors and industry experts together to make the right therapies for the right ALS patients and we will not stop until we have succeeded in our mission.
Kasper Roet
Chief Executive Officer
I was introduced only relatively recently to the challenge of ALS and its devastating course in patients. The need for effective treatment is so great that I have become quite obsessed about contributing, both by exploring ALS disease mechanisms in my academic lab and as cofounder of QurAlis, and will not rest until we have made a meaningful impact in halting or preventing the disease.
Clifford J. Woolf
Founder
For the first time in history we have genuine reason to believe we can cure patients with some forms of ALS in the next ten years.
Jonathan J. Fleming
Executive Chair
We have known so little about why motor neurons degenerate in ALS that it has been difficult to generate candidate therapeutics with the precision required for them to become actual cures. The transformative genetic and stem cell technologies being employed at Quralis will allow us to test candidate therapeutics on motor neurons derived from patients during their development, greatly increasing our likelihood of eventual successful in later clinical trials.